Department of Neurology, Glostrup Research Institute, Glostrup Hospital, Faculty of Health Sciences, University of Copenhagen, Glostrup, Denmark.
Headache. 2010 Jun;50(6):1017-30. doi: 10.1111/j.1526-4610.2010.01679.x. Epub 2010 May 7.
The goal of this study was to determine the vascular effects of protease-activated receptor-2 (PAR-2) activation in the rat cranial vasculature.
The role of PAR-2 in pain and inflammatory conditions has been established but the information available on its effects and receptor distribution in the trigeminal vascular axis is limited. We studied the dilatory function and expression of PAR-2 in the neuro-vascular circuit, critical in migraine pathogenesis. We also investigated the interaction of PAR-2 with calcitonin gene-related peptide (CGRP) and dural mast cells.
We used an improved model of intravital microscopy on the closed cranial window in rats to study the vascular effects of PAR-2 activating peptides (PAR-2 APs; SLIGRL-NH(2), 2-Furoyl-LIGRLO-NH(2)) in the dural vasculature. Measurement of immunoreactive CGRP in skull halves and in trigeminal nucleus caudalis was done by using an enzyme-linked immunosorbent assay. We also analyzed the presence of PAR-2 in different migraine relevant tissues by quantitative real-time PCR and Western blot analysis.
PAR-2 APs and trypsin induced a dose-dependent increase in dural artery diameter. The topical application of a nonspecific nitric oxide synthase (NOS) inhibitor, L-N(G)-Nitroarginine methyl ester, attenuated SLIGRL-NH(2) responses. Olcegepant, a CGRP receptor antagonist, did not a have significant effect on the SLIGRL-NH(2) responses, though exogenous CGRP responses were completely blocked. There was no significant release of CGRP from skull halves incubated with SLIGRL-NH(2) as compared with those incubated with the corresponding negative peptide. Chronic mast cell degranulation did not change the vascular effects of PAR-2 APs. mRNA and protein expression of PAR-2 were found throughout trigeminovasuclar axis.
PAR-2 activation leads to vasodilation of dural arteries and these responses are partially mediated by nitric oxide. As PAR-2 is present throughout trigeminovasuclar axis, it may have a role in migraine pathogenesis, independent of CGRP and mast cell mediated mechanism.
本研究旨在确定蛋白酶激活受体-2(PAR-2)在大鼠颅脑血管中的血管作用。
PAR-2 在疼痛和炎症中的作用已得到确立,但有关其在三叉血管轴中的作用和受体分布的信息有限。我们研究了在偏头痛发病机制中至关重要的神经血管回路中 PAR-2 的扩张功能和表达。我们还研究了 PAR-2 与降钙素基因相关肽(CGRP)和脑膜肥大细胞的相互作用。
我们使用大鼠封闭颅窗的改良活体显微镜模型研究了 PAR-2 激活肽(PAR-2 AP;SLIGRL-NH(2),2-呋喃酰基-LIGRLO-NH(2))在脑膜血管中的血管作用。通过酶联免疫吸附试验测量颅骨半胱氨酸和三叉神经尾核中的免疫反应性 CGRP。我们还通过定量实时 PCR 和 Western blot 分析分析了不同偏头痛相关组织中 PAR-2 的存在。
PAR-2 AP 和胰蛋白酶诱导脑膜动脉直径呈剂量依赖性增加。局部应用非特异性一氧化氮合酶(NOS)抑制剂 L-N(G)-硝基精氨酸甲酯可减弱 SLIGRL-NH(2)的反应。CGRP 受体拮抗剂 Olcegepant 对 SLIGRL-NH(2)的反应没有明显影响,尽管外源性 CGRP 反应完全被阻断。与用相应的阴性肽孵育的颅骨相比,用 SLIGRL-NH(2)孵育的颅骨没有明显的 CGRP 释放。慢性肥大细胞脱颗粒不会改变 PAR-2 AP 的血管作用。PAR-2 的 mRNA 和蛋白表达贯穿三叉血管轴。
PAR-2 激活导致脑膜动脉扩张,这些反应部分由一氧化氮介导。由于 PAR-2 存在于三叉血管轴的整个过程中,因此它可能在偏头痛发病机制中发挥作用,而与 CGRP 和肥大细胞介导的机制无关。